A vancomycin blood test measures the amount of vancomycin circulating in the blood so the dose can be adjusted for both effectiveness and safety. Vancomycin is an antibiotic used for serious gram-positive bacterial infections, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Because the drug is cleared mostly by the kidneys and can build up when kidney function changes, blood level monitoring is often part of treatment.
Older monitoring focused mainly on the trough level, which is the lowest concentration before the next dose. Current practice for serious MRSA infections often uses AUC monitoring, which estimates total drug exposure over 24 hours. A result is not interpreted by the number alone. The timing of the blood draw, dose schedule, kidney function, infection severity, organism susceptibility, and other medicines all affect what the result means.
- A vancomycin trough is usually drawn within 30 minutes before the next IV dose.
- For serious MRSA infections, many protocols target an AUC/MIC of 400–600, assuming an MIC of 1 mg/L.
- Traditional trough targets were often 10–15 mcg/mL or 15–20 mcg/mL, but trough-only targeting of 15–20 mcg/mL is no longer preferred for many serious MRSA infections.
- High vancomycin exposure can raise the risk of acute kidney injury, especially with unstable kidney function or other nephrotoxic drugs.
- Oral vancomycin usually does not need blood level monitoring because it is poorly absorbed, except in unusual high-risk situations.
Table of Contents
- What the Vancomycin Blood Test Measures
- Trough Level Timing and Meaning
- AUC Monitoring and Therapeutic Range
- High, Low, and Toxic Results
- Kidney Function and Safety Monitoring
- Why Results Can Be Misleading
- What Happens After an Abnormal Result
- Patient Questions to Ask
What the Vancomycin Blood Test Measures
A vancomycin blood test measures the concentration of vancomycin in serum or plasma, usually reported as mcg/mL, which is equivalent to mg/L. The test helps the care team adjust the dose so the infection receives enough antibiotic exposure without pushing the level higher than needed.
Vancomycin is most often monitored when it is given intravenously for serious infections. IV vancomycin enters the bloodstream directly and is used for infections such as MRSA bloodstream infection, endocarditis, pneumonia, bone and joint infection, meningitis, and severe skin or soft tissue infection. The blood level helps show how the patient’s body is handling the drug.
Oral vancomycin is different. When taken by mouth for Clostridioides difficile colitis, it usually stays inside the gut and is not absorbed into the bloodstream in meaningful amounts. For that reason, routine vancomycin blood levels are generally not used for standard oral vancomycin treatment. Blood level monitoring may be considered in unusual cases, such as severe colitis with kidney impairment, very high oral doses, prolonged therapy, or concern for unexpected absorption.
Vancomycin monitoring belongs to the broader practice of therapeutic drug monitoring, where drug levels are used to guide dosing for medicines with a narrow safety margin. The result is never interpreted like a simple “normal” or “abnormal” screening test. It is interpreted against a target chosen for the infection, the organism, and the patient’s changing kidney function.
Several details matter:
- The exact dose and dose interval
- The time the last dose started and ended
- The time the blood sample was drawn
- Current creatinine and estimated kidney function
- Whether the patient is critically ill, pregnant, obese, burned, or on dialysis
- Whether other kidney-stressing medicines are being used
- The infection site and organism susceptibility
For many patients, the vancomycin result is one part of a larger daily picture. Fever curve, white blood cell count, cultures, imaging, source control, fluid status, and kidney markers may all matter as much as the vancomycin number itself.
Trough Level Timing and Meaning
A trough level is the lowest expected vancomycin concentration in the dosing cycle. It is usually drawn just before the next IV dose, often within 30 minutes of that dose. The trough is useful because it is easy to collect and can show whether vancomycin is accumulating or clearing faster than expected.
Historically, many hospitals used trough-based targets. A trough of 10–15 mcg/mL was often used for less severe infections, while 15–20 mcg/mL was used for serious MRSA infections. Those older targets were partly chosen because troughs were easier to measure than total exposure. They were also used as a rough substitute for the AUC, which is a better measure of total vancomycin exposure.
Current guidance has shifted away from using trough-only targets of 15–20 mcg/mL for serious MRSA infections when AUC monitoring is available. Higher troughs can sometimes reflect excessive total exposure, and excessive exposure is linked with a higher risk of kidney injury. A trough can still be useful, but it is a limited snapshot.
| Trough pattern | Possible meaning | Common next step |
|---|---|---|
| Below target | The dose may be too low, the interval may be too long, or the patient may be clearing the drug quickly. | Confirm timing, review doses, and consider a dose increase or shorter interval. |
| Within target | The level fits the chosen trough goal, but AUC may still be needed for serious MRSA infection. | Continue monitoring based on clinical status and kidney function. |
| Above target | The drug may be accumulating, especially if kidney function has worsened or the sample was drawn too early. | Recheck timing, review kidney function, hold or reduce doses if needed. |
| Unexpectedly high or low | The blood draw may not match the documented schedule, or a dose may have been delayed, missed, or infused late. | Reconstruct the dosing timeline before changing therapy. |
A trough drawn too early can look falsely high. A trough drawn after the scheduled dose time, or after a delayed dose, can look falsely low. A result that does not match the patient’s dose history should be checked carefully before anyone assumes the body is clearing vancomycin unusually.
The trough also does not prove the infection is controlled. A patient can have a “good” trough and still need drainage of an abscess, removal of an infected catheter, repeat blood cultures, or a different antibiotic if the organism is not responding. For this reason, vancomycin monitoring works best when pharmacy, infectious disease, nursing, and the treating team all use the same dosing timeline.
AUC Monitoring and Therapeutic Range
AUC stands for “area under the concentration-time curve.” It estimates total vancomycin exposure over a period of time, usually 24 hours. For serious MRSA infections, the commonly recommended AUC/MIC target is 400–600 when the organism’s vancomycin MIC is assumed or confirmed to be 1 mg/L.
MIC means minimum inhibitory concentration. It is the lowest antibiotic concentration that inhibits growth of the organism in the laboratory. AUC/MIC combines the patient’s drug exposure with the organism’s susceptibility. If the MIC is higher, achieving an effective AUC/MIC may require more exposure, but pushing vancomycin exposure too high can raise toxicity risk. When the MIC is high or the infection is not improving, clinicians may consider alternative antibiotics instead of simply increasing vancomycin.
AUC monitoring can be done in two main ways. One approach uses Bayesian dosing software, which combines patient data, dosing history, blood levels, and population pharmacokinetic models to estimate exposure. Another approach uses two measured levels, often a post-infusion level and a trough, to calculate exposure with pharmacokinetic equations. Many hospitals prefer Bayesian AUC monitoring because it can often estimate exposure earlier and may use fewer blood draws once the system has enough information.
AUC monitoring is especially useful when the patient has:
- Serious MRSA infection
- Critical illness or sepsis
- Rapidly changing kidney function
- Obesity or very low body weight
- Burns or major fluid shifts
- Dialysis or other renal replacement therapy
- A long expected treatment course
- Concurrent nephrotoxic medicines
- Unexpected trough results
The usual AUC target for serious MRSA infections is not “as high as possible.” It is a range. An AUC below about 400 may risk underexposure in serious MRSA disease. An AUC above 600 raises concern for unnecessary exposure, and risk appears to rise further when exposure climbs above that range. The safest effective dose is usually preferred over a dose that produces a high trough just to reach an older target.
A related article on vancomycin trough and AUC monitoring can help readers compare the two approaches in more detail, but the main distinction is simple: a trough is one point in time, while AUC estimates total exposure.
High, Low, and Toxic Results
A vancomycin result is “high” or “low” only in relation to the target chosen for that patient. A trough of 13 mcg/mL may be acceptable in one setting and too low in another. An AUC of 500 may be appropriate for serious MRSA infection, while an AUC above 600 may trigger dose reduction depending on the full situation.
Low results can happen when the dose is too small, the interval between doses is too long, or the patient clears vancomycin faster than expected. Some patients clear the drug quickly because of augmented renal clearance, which can occur in younger trauma patients, some critically ill patients, burn patients, and others with high kidney filtration. Low levels can also happen when doses are missed, delayed, stopped early, or recorded incorrectly.
High results can happen when kidney function worsens, the dose is too large, the interval is too short, or a blood sample is drawn at the wrong time. A patient who was clearing vancomycin well on Monday may accumulate it by Wednesday if dehydration, sepsis, contrast exposure, surgery, or another kidney stressor develops.
| Result pattern | Why it matters | Information needed before action |
|---|---|---|
| Low trough or low AUC | May reduce the chance of effective treatment in serious infection. | Culture results, infection site, dose history, kidney function, and timing of draw. |
| High trough with acceptable AUC | May not require the same response as a high AUC, depending on protocol. | Whether the trough was used alone or as part of AUC modeling. |
| High AUC | Suggests excessive total exposure and higher kidney risk. | Creatinine trend, urine output, nephrotoxic drugs, and infection response. |
| Rising levels over several days | May signal accumulation before obvious symptoms appear. | Daily renal markers, fluid balance, dose changes, and medication list. |
“Toxic level” is not a single universal number. Toxicity risk rises across a continuum as exposure increases, especially when other risk factors are present. A trough persistently above 15–20 mcg/mL or an AUC above the recommended range may increase concern, but the patient’s kidney function, duration of therapy, and other medications often determine the real level of risk.
Symptoms that deserve prompt attention during vancomycin therapy include reduced urination, new swelling, unusual weakness, ringing in the ears, hearing changes, severe dizziness, widespread rash, mouth sores, blistering skin, fever with rash, wheezing, chest or back tightness during infusion, and faintness or low blood pressure. Vancomycin infusion reaction can happen when IV vancomycin is infused too quickly and may cause flushing, itching, redness of the upper body, and sometimes hypotension. It is not the same as a high trough level, but it still needs immediate clinical attention.
Kidney Function and Safety Monitoring
Kidney function is central to vancomycin monitoring because IV vancomycin is cleared mainly through the kidneys. When kidney function drops, vancomycin can remain in the body longer and accumulate. When kidney clearance is unusually high, levels can fall below the desired exposure.
Creatinine is the most common blood marker used to follow kidney function during treatment. A rising creatinine can suggest acute kidney injury, although creatinine changes may lag behind the actual injury. Estimated glomerular filtration rate, urine output, BUN, fluid balance, and the broader clinical picture may also be reviewed. Readers who want more background on these markers may find creatinine and eGFR interpretation useful.
Vancomycin-associated kidney injury is usually discussed as acute kidney injury rather than chronic kidney disease. It may be reversible, especially when recognized early, but it can be serious in critically ill patients. The cause is often multifactorial. Sepsis, dehydration, low blood pressure, contrast dye, surgery, heart failure, and other antibiotics can all contribute. Vancomycin exposure may be one part of that risk.
Medicines that can increase kidney stress during vancomycin therapy include aminoglycosides, amphotericin B, IV contrast, loop diuretics, nonsteroidal anti-inflammatory drugs, tacrolimus, cyclosporine, and some antibiotic combinations. Gentamicin and other aminoglycosides have their own level monitoring needs, and the principles overlap with gentamicin peak and trough testing.
Safety monitoring may include:
- Serum creatinine and estimated kidney function
- Vancomycin AUC or trough levels
- Urine output in hospitalized or critically ill patients
- Complete blood count during prolonged therapy
- Hearing symptoms if exposure is high or other ototoxic drugs are used
- Skin and liver-related symptoms if a hypersensitivity reaction is suspected
A mild creatinine rise may prompt closer monitoring, dose adjustment, or a change in antibiotic plan. A larger or continuing rise may require holding vancomycin, spacing doses farther apart, switching therapy, evaluating other kidney stressors, and involving infectious disease, pharmacy, or nephrology.
Why Results Can Be Misleading
Vancomycin results can be misleading when the blood draw timing is wrong. A trough should be drawn just before the next dose. If it is drawn one or two hours too early, the concentration may look higher than the true trough. If the dose was delayed but the blood draw was still taken at the original time, the result may look lower than expected.
Documentation errors also matter. The care team needs to know when the dose actually started, when the infusion ended, whether the full dose was given, and whether any doses were missed. In a busy hospital setting, the scheduled time and the real administration time may differ. A single result should be interpreted only after the timeline is checked.
Kidney function can change faster than the dosing plan. A patient may start therapy with normal creatinine and then develop acute kidney injury from sepsis, dehydration, low blood pressure, contrast imaging, or another medication. The same vancomycin dose can become too much within a short period. The reverse can also happen: some patients clear vancomycin faster during recovery, after fluid resuscitation, or with augmented renal clearance.
Body size and fluid shifts can also affect levels. In severe illness, vancomycin may distribute into a larger fluid volume, especially after large IV fluid amounts, burns, edema, or critical illness. This can make early levels harder to predict. In obesity, dosing and AUC estimation need careful protocol-based adjustment because simple weight-based assumptions may overestimate or underestimate exposure.
The infection itself changes interpretation. A low vancomycin level in a mild infection does not mean the same thing as a low level during MRSA bacteremia or endocarditis. A high vancomycin level in a patient whose cultures now show a different organism may not justify continuing vancomycin at all. Culture results, susceptibility testing, source control, and clinical response should guide whether vancomycin remains the right drug.
Lab methods can also vary. Many laboratories use immunoassays for vancomycin. Some specialized settings use liquid chromatography-based methods. Small differences between methods usually do not matter as much as timing and clinical context, but they can contribute to confusion when patients transfer between hospitals.
What Happens After an Abnormal Result
After an abnormal vancomycin result, the first step is usually to confirm whether the result is believable. Clinicians often reconstruct the dosing timeline before changing the dose. They check the previous dose time, infusion duration, blood draw time, current dose, kidney function, urine output, and whether the patient received other nephrotoxic medicines.
If the result is low and the infection still requires vancomycin, the dose may be increased, the interval may be shortened, or an AUC-based plan may be recalculated. In serious MRSA infections, the team may try to reach the AUC target early, often within the first 24–48 hours, while still avoiding excessive exposure.
If the result is high, the next step may be to hold the next dose, reduce the dose, extend the interval, or repeat a level before restarting. When kidney function is unstable, the team may dose “by level,” meaning they wait for the concentration to fall into a safer range before giving another dose. This is common in patients with acute kidney injury or dialysis.
If the patient is improving and cultures no longer support vancomycin, the best response may be to stop vancomycin rather than adjust it. Antibiotic stewardship is part of safety. A drug level should not keep a patient on vancomycin if the infection can be treated with a narrower or safer option.
An abnormal result may also trigger additional testing. A rising creatinine may lead to a broader kidney evaluation, medication review, fluid assessment, or nephrology input. Background information on high creatinine blood test results can help readers understand why kidney markers receive so much attention during vancomycin therapy.
Patients should not change vancomycin dosing on their own. In the hospital, dose timing and lab timing are coordinated. For outpatient IV therapy, the infusion service, pharmacist, and prescriber usually need exact times for home doses and blood draws. A “random” level can still be useful in some situations, but only if the team knows how long it was drawn after the last dose.
Patient Questions to Ask
Patients and caregivers can help prevent confusing results by asking clear questions about timing. The most useful question is often, “When should the blood draw happen compared with my dose?” For trough monitoring, the answer is usually just before the next dose. For AUC monitoring, the team may request one or two samples at specific times.
Useful questions include:
- Is my vancomycin being monitored by trough, AUC, or both?
- What target range is being used for my infection?
- Was my blood sample drawn at the correct time?
- How is my kidney function changing?
- Am I taking any other medicines that increase kidney or hearing risk?
- Should I report ringing in the ears, dizziness, rash, itching, or reduced urination right away?
- If I am receiving home IV therapy, whom should I call if a dose or blood draw is late?
For home infusion, keeping a simple written log can be very helpful. The log should include the start and stop time of each infusion, missed or delayed doses, blood draw time, new symptoms, and any medication changes. This information can prevent unnecessary dose changes based on a level that only looks abnormal because the sample was mistimed.
Patients should also understand why the target may change. If cultures identify a different organism, if kidney function changes, if dialysis starts or stops, or if the infection improves enough to switch antibiotics, the vancomycin plan may change quickly. The safest plan is the one that fits the current infection and the current kidney function, not the one that matched the first day of treatment.
References
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists 2020 (Guideline)
- ASHP/PIDS/SIDP/IDSA Revised Consensus Guideline and Review for Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections 2020 (Guideline)
- Vancomycin 2024 (Review)
- Vancomycin: MedlinePlus Drug Information 2022 (Official Drug Information)
- Ototoxicity of Non-aminoglycoside Antibiotics 2021 (Review)
- Vancomycin 2025 (Review)
Disclaimer
Vancomycin blood test results should be interpreted by a qualified clinician who can review the dose timing, infection type, kidney function, and other medicines. This information is for general education and is not a substitute for medical care. Seek urgent medical help for severe allergic symptoms, trouble breathing, fainting, blistering rash, sudden hearing changes, or a major drop in urination during treatment.
